Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02417974 · ClinicalTrials.gov registry record · Phase 2
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02417974 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT02417974, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this trial is to assess if Fecal Microbiota Therapy (FMT) can reduce the risk of endoscopic recurrence of Crohn's disease (CD) in patients after intestinal resection. The specific outcomes of FMT to be examined are: 1) endoscopic appearance, 2) clinical symptoms, 3) safety and tolerability, and 4) microbial diversity. The research team hypothesizes that FMT will prevent establishment of "pro-inflammatory" microbiome after surgery, leading to a reduced probability of recurrence of macroscopic inflammation. It is also hypothesized that FMT will be safe and well-tolerated in these patients.
Interventions
- BIOLOGICAL Fecal Microbiota Transplant (FMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02417974
The ClinicalTrials.gov registry entry for NCT02417974 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fecal Microbiota Transplant (FMT) is the first listed.
NCT02417974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02417974 about?
NCT02417974 is a clinical study titled "Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)". The objective of this trial is to assess if Fecal Microbiota Therapy (FMT) can reduce the risk of endoscopic recurrence of Crohn's disease (CD) in patients after intestinal resection. The specific outcomes of FMT to be examined are: 1) endoscopic appearance, 2) clinical symptoms, 3) safety and toler...
What is the current status of trial NCT02417974?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-09. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT02417974?
The interventions under investigation include: Fecal Microbiota Transplant (FMT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02417974?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.